Trial Profile
Multicenter, Randomized, Open Label Trial to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Treprostinil (Primary)
- Indications Pulmonary fibrosis; Pulmonary hypertension
- Focus Therapeutic Use
- Sponsors United Therapeutics Corporation
- 08 Feb 2016 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
- 17 Nov 2015 New trial record